Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

43.62CHF
4:31pm GMT
Change (% chg)

CHF-0.82 (-1.85%)
Prev Close
CHF44.44
Open
CHF44.32
Day's High
CHF44.68
Day's Low
CHF43.22
Volume
38,277
Avg. Vol
74,667
52-wk High
CHF81.45
52-wk Low
CHF43.22

Select another date:

Mon, Dec 10 2018

BRIEF-Basilea Pharmaceutica: CHF 10 Million Milestone Payment For Cresemba Sales

* CONTINUED STRONG CRESEMBA® (ISAVUCONAZOLE) U.S. SALES PERFORMANCE BY ASTELLAS PHARMA INC. TRIGGERS CHF 10 MILLION MILESTONE PAYMENT TO BASILEA

BRIEF-Basilea Presents Preclinical Data On Anticancer Drug Candidate Bal101553 At Eortc-Nci-Aacr Symposium

* BASILEA PRESENTS PRECLINICAL DATA ON ITS ANTICANCER DRUG CANDIDATE BAL101553 AT EORTC-NCI-AACR SYMPOSIUM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica Sees 2018 Oper Loss At CHF 25-35 Mln

* H1 OPERATING LOSS OF CHF 20.4 MILLION COMPARED TO CHF 19.1 MILLION IN H1 2017

BRIEF-Basilea Pharmaceutica: Approval For Antifungal Cresemba (Isavuconazole) In Jordan

* HIKMA PHARMACEUTICALS LLC, GAINED REGULATORY APPROVAL FOR ANTIFUNGAL CRESEMBA (ISAVUCONAZOLE) IN JORDAN Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Starts Clinical Phase 3 Study With Antibiotic Ceftobiprole In Staphylococcus Aureus Bacteremia

* BASILEA STARTS CLINICAL PHASE 3 STUDY WITH ANTIBIOTIC CEFTOBIPROLE IN STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica Reports Receipt Of Payment Based On First Cresemba Approval In Latin America

* REPORTS RECEIPT OF MILESTONE PAYMENT BASED ON FIRST CRESEMBA® APPROVAL IN LATIN AMERICA

BRIEF-Basilea Pharmaceutica Starts Clinical Phase 2A Expansion With Bal101553 In Ovarian Cancer And Glioblastoma

* STARTS CLINICAL PHASE 2A EXPANSION WITH BAL101553 IN OVARIAN CANCER AND GLIOBLASTOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: